James Williams

About

James is an accomplished scientist, entrepreneur and investor. He has been involved from concept to commercialisation, including CEO, CTO and Board roles, of numerous biotech companies which have resulted in five FDA approved drugs and devices. He conceived the technology behind iCeutica Inc (acquired in 2011) and co-discovered the lead therapy for ASX-listed Dimerix Limited (ASX:DXB), currently in Phase 3 trials for Chronic Kidney Disease. James is involved in all phases of investment across the Yuuwa portfolio, and is currently a Director of PolyActiva Pty Ltd and alternate Director of Adalta Limited (ASX:1AD). He remains Chairman of Dimerix and is on the Board of the Perron Institute for Neurological and Translational Science.

Source (opens in a new tab)